Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vera Therapeutics, Inc.

21.43
-1.1400-5.05%
Volume:1.45M
Turnover:31.79M
Market Cap:1.37B
PE:-5.97
High:22.77
Open:22.43
Low:21.40
Close:22.57
52wk High:51.61
52wk Low:18.53
Shares:63.82M
Float Shares:42.92M
Volume Ratio:0.78
T/O Rate:3.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5921
EPS(LYR):-2.7500
ROE:-54.83%
ROA:-30.24%
PB:2.92
PE(LYR):-7.79

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: West Pharmaceutical Services (WST), Blueprint Medicines (BPMC) and Vera Therapeutics (VERA)

TIPRANKS
·
Jun 03

Small U.S. Stocks End Mixed As Vera Therapeutics Lead, Diginex Lags

Dow Jones
·
Jun 03

BUZZ-U.S. STOCKS ON THE MOVE-Natgas companies, UnitedHealth, Cactus

Reuters
·
Jun 03

Vera Therapeutics Is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
Jun 03

Wedbush Raises Price Target on Vera Therapeutics to $32 From $26, Maintains Neutral Rating

MT Newswires Live
·
Jun 03

J.P. Morgan Remains a Buy on Vera Therapeutics (VERA)

TIPRANKS
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Lyra Therapeutics, Church & Dwight, Applied Digital

Reuters
·
Jun 02

Vera Therapeutics price target raised to $65 from $55 at Scotiabank

TIPRANKS
·
Jun 02

Vera Therapeutics (VERA) Receives a Buy from Guggenheim

TIPRANKS
·
Jun 02

Evercore ISI Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

TIPRANKS
·
Jun 02

Buy Rating for Vera Therapeutics: Promising Potential of Atacicept in IgA Nephropathy Treatment

TIPRANKS
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera

Reuters
·
Jun 02

Arthur He CFA Upgrades Vera Therapeutics on Promising Phase 3 Results for Atacicept in IgAN Treatment

TIPRANKS
·
Jun 02

BRIEF-Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy

Reuters
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Blueprint Medicines, Boeing

Reuters
·
Jun 02

Top Premarket Gainers

MT Newswires Live
·
Jun 02

BUZZ-Vera Therapeutics jumps after kidney disease drug succeeds in late-stage trial

Reuters
·
Jun 02

Vera Therapeutics Announces Positive Phase 3 Trial Results

TIPRANKS
·
Jun 02

Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept

TIPRANKS
·
Jun 02

Vera Therapeutics Announces Successful Completion of Phase 3 Trial for Atacicept; Plans to Submit BLA for FDA Approval in IgA Nephropathy by Q4 2025

Reuters
·
Jun 02